CCL2 and head and neck cancer: Clinically, while GSVA scoring showed an inverse correlation between the gefitinib-induced gene set and poor prognosis in head and neck cancer (The Cancer Genome Atlas (TCGA) data, Figure 2F), CCL2 exhibited a distinct pattern: its elevated expression significantly associated with worse survival outcomes (Figure 2G) and enhanced macrophage infiltration (Figure 2H).